|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-3-18
|
|
pubmed:abstractText |
Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations present at high frequency in human tumors and have been shown to be associated with resistance to radio-chemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited for therapeutic advantage using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-10428201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-10683383,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-11716177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-11895891,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-12214265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-12724731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-14663486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-14704432,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-15753391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-15865941,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-15865943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-15899832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-16299248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-16443686,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17079445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17126603,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17138942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17198971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17227293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17322917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17668425,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-17671205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-18340116,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-18451145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-18469851,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-18501095,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-18834305,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-19301654,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-19464524,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20178585-19737973
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
57
|
|
pubmed:meshHeading |
pubmed-meshheading:20178585-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20178585-Apoptosis,
pubmed-meshheading:20178585-Camptothecin,
pubmed-meshheading:20178585-Cell Line, Tumor,
pubmed-meshheading:20178585-Drug Screening Assays, Antitumor,
pubmed-meshheading:20178585-Flow Cytometry,
pubmed-meshheading:20178585-Fluorouracil,
pubmed-meshheading:20178585-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:20178585-Humans,
pubmed-meshheading:20178585-Imidazoles,
pubmed-meshheading:20178585-Lung Neoplasms,
pubmed-meshheading:20178585-Models, Genetic,
pubmed-meshheading:20178585-Mutation,
pubmed-meshheading:20178585-Piperazines,
pubmed-meshheading:20178585-Purines,
pubmed-meshheading:20178585-Tumor Suppressor Protein p53
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment.
|
|
pubmed:affiliation |
OncoRay - Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Fetscherstrasse 74/PO Box 86, 01307 Dresden, Germany. Sergey.Tokalov@oncoray.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
